Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis. (PubMed, Blood Neoplasia) - Oct 19, 2026 - "There was a higher rate of infections in trial-ineligible patients than in trial-eligible patients (45% vs 21%; P = .043). These findings support the use of mosun in the treatment of relapsed/refractory indolent lymphomas, even in trial-ineligible patients."
Journal • Real-world evidence • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD20
|
|
Ajay Major; Alex F Herrera; Allison M Bock; Amy Ayers; Andrew P Jallouk; Ayushi Chauhan; Christopher R Flowers; Geoffrey Shouse; Gilles Salles; Jennifer L Crombie; Lorenzo Falchi; Mathew A Lunning; Mehdi Hamadani; Narendranath Epperla; Omnia Farahat; Reid W Merryman; Sairah Ahmed; Shakthi T Bhaskar; Sonia Godbole; Steven Bair; Swetha K Thiruvengadam; Yazeed Sawalha
|